TY - JOUR
T1 - Management of psoriasis in patients with inflammatory bowel disease
T2 - From the Medical Board of the National Psoriasis Foundation
AU - Whitlock, Scott M.
AU - Enos, Clinton W.
AU - Armstrong, April W.
AU - Gottlieb, Alice
AU - Langley, Richard G.
AU - Lebwohl, Mark
AU - Merola, Joseph F.
AU - Ryan, Caitriona
AU - Siegel, Michael P.
AU - Weinberg, Jeffrey M.
AU - Wu, Jashin J.
AU - Van Voorhees, Abby S.
N1 - Publisher Copyright:
© 2017 American Academy of Dermatology, Inc.
PY - 2018/2
Y1 - 2018/2
N2 - Background: There is a significant association between psoriasis and inflammatory bowel disease (IBD). Many treatments for psoriasis and psoriatic arthritis are also used for IBD. Objective: To assess therapeutic options for patients with psoriasis and concurrent IBD. Methods: A systematic literature search was performed for clinical studies of biologic and systemic psoriasis medications in psoriasis, psoriatic arthritis, ulcerative colitis, and Crohn's disease, for the period from January 1, 1947, to February 14, 2017. Randomized, controlled, double-blinded studies were selected if available. If not, the next highest level of available evidence was selected. Results: Of the 2282 articles identified, 132 were selected. Infliximab and adalimumab have demonstrated efficacy in psoriasis, psoriatic arthritis, ulcerative; colitis, and Crohn's disease. Ustekinumab has demonstrated efficacy in psoriasis, psoriatic arthritis, and Crohn's disease. Certolizumab has demonstrated efficacy in psoriatic arthritis and Crohn's disease. Etanercept, secukinumab, brodalumab, and ixekizumab have demonstrated efficacy in psoriasis and psoriatic arthritis but may exacerbate or induce IBD. Guselkumab has demonstrated efficacy in psoriasis. Limitations: There are no known clinical trials of treatment specifically for concurrent psoriasis and IBD. Conclusions: Infliximab and adalimumab have demonstrated efficacy in psoriasis, psoriatic arthritis, ulcerative colitis, and Crohn's disease; other agents have demonstrated efficacy for some, but not all, of these indications.
AB - Background: There is a significant association between psoriasis and inflammatory bowel disease (IBD). Many treatments for psoriasis and psoriatic arthritis are also used for IBD. Objective: To assess therapeutic options for patients with psoriasis and concurrent IBD. Methods: A systematic literature search was performed for clinical studies of biologic and systemic psoriasis medications in psoriasis, psoriatic arthritis, ulcerative colitis, and Crohn's disease, for the period from January 1, 1947, to February 14, 2017. Randomized, controlled, double-blinded studies were selected if available. If not, the next highest level of available evidence was selected. Results: Of the 2282 articles identified, 132 were selected. Infliximab and adalimumab have demonstrated efficacy in psoriasis, psoriatic arthritis, ulcerative; colitis, and Crohn's disease. Ustekinumab has demonstrated efficacy in psoriasis, psoriatic arthritis, and Crohn's disease. Certolizumab has demonstrated efficacy in psoriatic arthritis and Crohn's disease. Etanercept, secukinumab, brodalumab, and ixekizumab have demonstrated efficacy in psoriasis and psoriatic arthritis but may exacerbate or induce IBD. Guselkumab has demonstrated efficacy in psoriasis. Limitations: There are no known clinical trials of treatment specifically for concurrent psoriasis and IBD. Conclusions: Infliximab and adalimumab have demonstrated efficacy in psoriasis, psoriatic arthritis, ulcerative colitis, and Crohn's disease; other agents have demonstrated efficacy for some, but not all, of these indications.
KW - Crohn's disease
KW - IBD
KW - inflammatory bowel disease
KW - psoriasis
KW - psoriatic arthritis
KW - ulcerative colitis
UR - http://www.scopus.com/inward/record.url?scp=85044649902&partnerID=8YFLogxK
U2 - 10.1016/j.jaad.2017.06.043
DO - 10.1016/j.jaad.2017.06.043
M3 - Review article
C2 - 29332708
AN - SCOPUS:85044649902
SN - 0190-9622
VL - 78
SP - 383
EP - 394
JO - Journal of the American Academy of Dermatology
JF - Journal of the American Academy of Dermatology
IS - 2
ER -